This joint guidance by the ECDC and EMCDDA aims to strengthen the evidence base for developing national strategies for preventing and controlling infections and infectious diseases among people who inject drugs.
This document is an update of the joint guidance that was published in 2011 by the European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).
This document outlines operational considerations to support the continuity of national surveillance systems and public health laboratories for epidemiological and virological surveillance for influenza, SARS-CoV-2, and potentially other respiratory viruses in the 2022/2023 winter season and beyond.
This document provides guidance on diagnostic testing, molecular characterisation and metagenomic analysis for suspect cases of severe acute hepatitis of unknown aetiology.
Urgent action is required to improve efforts to prevent hepatitis B and C infections in the EU/EEA and the UK if the region is to meet the 2020 targets for the elimination of viral hepatitis as a serious threat to public health. Significant gaps in the reported data in relation to prevalence and prevention of HBV and HCV in EU/EEA and the UK present a major challenge to monitoring progress towards the targets for elimination of hepatitis.
The influenza vaccination communication guide provide advice, guidance and campaign materials to support national influenza vaccination campaigns with the purpose of increasing the influenza vaccination uptake in the EU Member States.
This operational guidance, developed by ECDC in collaboration with its hepatitis E virus (HEV) expert group, offers options on the implementation or adjustment of HEV surveillance at a national level.
The ECDC guidance on integrated testing of hepatitis B (HBV), hepatitis C (HCV) and HIV supports countries in the global effort to combat viral hepatitis and eliminate HIV as public health threats by 2030. At present, reaching and testing those at risk of infection with HIV, HBV or HCV is still a public health challenge across Europe. This Guidance in brief is based on the comprehensive guidance document which provides the evidence base for this guidance
This guidance aims to provide EU/EEA countries with an evidence-based framework to help develop, implement, monitor and evaluate their own national HBV, HCV and HIV testing guidelines and programmes.